mProX™ Human LILRB5 Stable Cell Line

Product Information

Target Family

Oncology

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1

Target Classification

Oncology Cell Lines

Gene ID

Human:10990

UniProt ID

Human:O75023

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

LILRB5, a gene associated with statin intolerance and statin-induced myalgia, has various applications in clinical trials and pharmacogenomic studies. In a clinical trial, the LILRB5 Asp247Gly genotype was found to modify the cholesterol-lowering effect of statins, with individuals carrying the Asp247Asp genotype experiencing a greater increase in creatine kinase and a lower reduction in non-HDL cholesterol compared to those with the Gly247Gly genotype. This suggests that the LILRB5 variant could be used for precision cardiovascular therapy. In another study, LILRB5 was identified as one of the genetic variants associated with statin-associated muscle symptoms (SAMS) in patients receiving atorvastatin or rosuvastatin. The study found a synergistic effect between LILRB5 and ABCB1 variants on statin response, indicating that these variants could be used to predict statin efficacy. Additionally, LILRB5 has been studied in the context of repetitive low-level blast exposure, where it was found to be downregulated in experienced breachers compared to unexposed controls. This suggests that LILRB5 may play a role in the immune response to blast exposure. Furthermore, LILRB5 expression has been analyzed in liver cancer, with downregulation of LILRB5 observed in liver cancer tissues. The expression of LILRB5 and other LILRB family members was associated with the prognosis of liver cancer patients and the infiltration of immune cells in the tumor microenvironment. These findings highlight the potential utility of LILRB5 in predicting statin response, understanding immune response in blast exposure, and assessing prognosis in liver cancer.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human LILRB5 Stable Cell Line (S01YF-1023-PY239). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Jordan Brown (Verified Customer)

How does LILRB5 genetic variation affect statin response? Apr 26 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

Variants in LILRB5 are associated with statin intolerance and modify the cholesterol-lowering effect of statins, highlighting its role in precision cardiovascular therapy. Apr 26 2020

chat Cameron Williams (Verified Customer)

What is the association between LILRB5 and mycobacteria exposure? Mar 05 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

Expression of LILRB5 on monocytes is associated with mycobacteria exposure, indicating its potential relevance in mycobacterial recognition and immune response. Mar 05 2020

Published Data

Fig.1 The expression of LILRB family on MDSC cells in patients with HCC.

The percentage of LILRB5 on MDSC from TFL was noted to be significantly increased compared to that from the tumor, despite the absence of a statistically significant distinction between them (A higher percentage was observed in TFL compared to the tumor, with values of 6.46%±2.99% and 0.072%±0.072%, respectively, p> 0.05). Furthermore, the percentage of LILRB1 expressed from the tumor was found to be significantly lower than that from the corresponding TFL (Tumor vs TFL: 4.82%±1.93% vs 20.60%±6.41%, p < 0.05).

Ref: Fan, Jing, et al. "Expression of leukocyte immunoglobulin-like receptor subfamily B expression on immune cells in hepatocellular carcinoma." Molecular Immunology 136 (2021): 82-97.

Pubmed: 34098344

DOI: 10.1016/j.molimm.2021.05.011

Research Highlights

Tornio, Aleksi. et al. "The cholesterol-lowering effect of statins is modified by LILRB5 intolerance genotype: Results from a recruit-by-genotype clinical trial." Frontiers in pharmacology, 2023.
This article reports a clinical trial that examined the effect of a genetic variant in LILRB5 on statin intolerance and cholesterol-lowering response. The trial found that individuals with the Asp247Asp genotype had higher creatine kinase levels and lower cholesterol reduction than those with the Gly247Gly genotype after taking atorvastatin. The authors suggest that this variant could be useful for precision cardiovascular therapy.
Tornio, Aleksi. et al. "The cholesterol-lowering effect of statins is modified by LILRB5 intolerance genotype: Results from a recruit-by-genotype clinical trial." Frontiers in pharmacology, 2023.
Pubmed: 36998609 DOI: 10.3389/fphar.2023.1090010

A Murphy, William. et al. "Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial." Circulation. Genomic and precision medicine, 2022.
Recent research indicates that the development of statin-associated muscle symptoms (SAMS) may be linked to a specific genetic variation in the 5'-AMP-activated protein kinase (PRKAA1) enzyme, specifically the p.Val174Ala missense variant. This variant has been observed in previous studies to be associated with an increased risk of SAMS among individuals undergoing statin therapy. SAMS are the most commonly reported adverse events associated with statin use, making this finding potentially significant in understanding and managing the side effects of these medications.
A Murphy, William. et al. "Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial." Circulation. Genomic and precision medicine, 2022.
Pubmed: 35543701 DOI: 10.1161/CIRCGEN.121.003503